Ethyl 2,6-difluoro-4-[(3-hydroxy-4-chloro-5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalene-2-carbonyl)-amino]-benzoate | 365430-75-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: Ethyl 2,6-difluoro-4-[(3-hydroxy-4-chloro-5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalene-2-carbonyl)-amino]-benzoate
• 英文别名: ethyl 4-[(4-chloro-3-hydroxy-5,5,8,8-tetramethyl-6,7-dihydronaphthalene-2-carbonyl)amino]-2,6-difluorobenzoate
• CAS: 365430-75-7
• 化学式: C₂₄H₂₆ClF₂NO₄
• 分子量: 465.925
• InChiKey: AGVFJTCMRKAWMC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  7.1
• 重原子数：
  32
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  75.6
• 氢给体数：
  2
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  Ethyl 2,6-difluoro-4-[(3-hydroxy-4-chloro-5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalene-2-carbonyl)-amino]-benzoate 在 sodium hydroxide 作用下， 以 乙醇 为溶剂， 生成 AGN 195183
  参考文献：
  名称：

  Synthesis and biological activity of retinoic acid receptor-α specific amides

  摘要：

  Retinoids are analogues of all-trans-retinoic acid, a powerful hormone that mediates many fundamental biological processes. Cancer and other serious hyperprolifierative diseases are attractive therapeutic targets for retinoids, but the therapeutic use of retinoids is limited due to severe toxicity. We report here the design of retinoid receptor-alpha specific ligands with growth inhibitory activity in breast cancer cell lines, and which do not cause the cutaneous toxicity associated with the currently available nonselective retinoid agonists. (C) 2002 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(02)00647-9
• 作为产物：
  描述：

  3-methoxy-5,6,7,8-tetrahydro-5,5,8,8-tetramethylnaphthalene-2-carboxylic acid 在 吡啶 、 氯化亚砜 、 三溴化硼 作用下， 以 乙醚 、 二氯甲烷 为溶剂， 生成 Ethyl 2,6-difluoro-4-[(3-hydroxy-4-chloro-5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalene-2-carbonyl)-amino]-benzoate
  参考文献：
  名称：

  Synthesis and biological activity of retinoic acid receptor-α specific amides

  摘要：

  Retinoids are analogues of all-trans-retinoic acid, a powerful hormone that mediates many fundamental biological processes. Cancer and other serious hyperprolifierative diseases are attractive therapeutic targets for retinoids, but the therapeutic use of retinoids is limited due to severe toxicity. We report here the design of retinoid receptor-alpha specific ligands with growth inhibitory activity in breast cancer cell lines, and which do not cause the cutaneous toxicity associated with the currently available nonselective retinoid agonists. (C) 2002 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(02)00647-9

文献信息

• Treatment of tumors with RARalpha selective retinoid compounds in combination with other anti-tumor agents
  申请人：Allergan Sales, Inc.

  公开号：US20010039293A1

  公开（公告）日：2001-11-08

  Compounds which are specific or selective agonists of RAR&agr; receptors in preference over RAR&bgr; and RAR&ggr; receptors, and particularly compounds of the formula 1 where R is a H, lower alkyl of 1 to 6 carbons, or a pharmaceutically acceptable salt, are useful for treating a malignant disease or condition in a mammal. In treatment of solid tumors the compound exhibit synergistic anti-proliferative effect with human recombinant interferon.

  具有特异性或选择性作用于RAR&agr;受体，而优先于RAR&bgr;和RAR&ggr;受体的化合物，尤其是公式1中R为H，1至6个碳的低烷基或药物可接受的盐的化合物，可用于治疗哺乳动物的恶性疾病或病况。在固体肿瘤的治疗中，该化合物与人重组干扰素表现出协同的抗增殖效应。
• Treatment of tumors with RAR&agr; selective retinoid compounds in combination with other anti-tumor agents
  申请人：Allergan Sales, Inc.

  公开号：US06387950B2

  公开（公告）日：2002-05-14

  Compounds which are specific or selective agonists of RAR&agr; receptors in preference over RAR&bgr; and RAR&ggr; receptors, and particularly compounds of the formula where R is a H, lower alkyl of 1 to 6 carbons, or a pharmaceutically acceptable salt, are useful for treating a malignant disease or condition in a mammal. In treatment of solid tumors the compound exhibit synergistic anti-proliferative effect with human recombinant interferon.

  该化合物是RAR&agr;受体的特异性或选择性激动剂，相对于RAR&bgr;和RAR&ggr;受体更具选择性。特别是公式中R为H，1到6个碳的低碳基或药学上可接受的盐的化合物，对于治疗哺乳动物的恶性疾病或病症是有用的。在固体肿瘤的治疗中，该化合物与人重组干扰素表现出协同的抗增殖效应。
• Treatment of tumors with RAR alpha selective retinoid compounds in combination with other anti-tumor agents
  申请人：ALLERGAN, INC.

  公开号：EP1650188A1

  公开（公告）日：2006-04-26

  Compounds which are specific or selective agonists of RARα receptors in preference over RARβ and RARγ receptors, and particularly compounds of the formula (I) where R is a H, lower alkyl of 1 to 6 carbons, or a pharmaceutically acceptable salt, are useful for treating a malignant disease or condition in a mammal. In treatment of solid tumors the compound exhibit synergistic antiproliferative effect with human recombinant interferon.

  与 RARβ 和 RARγ 受体相比，作为 RARα 受体的特异性或选择性激动剂的化合物，尤其是式 (I) 中 R 为 H、1-6 碳原子的低级烷基或药学上可接受的盐的化合物，可用于治疗哺乳动物的恶性疾病或病症。在治疗实体瘤时，该化合物与人重组干扰素具有协同抗增殖作用。
• Bioorg. Med. Chem. Lett. 2002, 12, 3145-3148
  作者：

  DOI：——

  日期：——
• TREATMENT OF TUMORS WITH RAR ALPHA SELECTIVE RETINOID COMPOUNDS IN COMBINATION WITH OTHER ANTI-TUMOR AGENTS
  申请人：ALLERGAN, INC.

  公开号：EP1268405B1

  公开（公告）日：2006-06-28